These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28157461)

  • 1. Multidrug-resistant tuberculosis patients' views of interventions to reduce treatment loss to follow-up.
    Tupasi T; Garfin AM; Mangan JM; Orillaza-Chi R; Naval LC; Balane GI; Basilio R; Golubkov A; Joson ES; Lew WJ; Lofranco V; Mantala M; Pancho S; Sarol JN; Blumberg A; Burt D; Kurbatova EV
    Int J Tuberc Lung Dis; 2017 Jan; 21(1):23-31. PubMed ID: 28157461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug-resistant tuberculosis patients lost to follow-up: self-reported readiness to restart treatment.
    Mangan JM; Tupasi TE; Garfin AM; Lofranco V; Orillaza-Chi R; Basilio R; Naval LC; Balane GI; Joson ES; Burt D; Lew WJ; Mantala M; Pancho S; Sarol JN; Golubkov A; Kurbatova EV
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1205-11. PubMed ID: 27510247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012-2014.
    Tupasi TE; Garfin AM; Kurbatova EV; Mangan JM; Orillaza-Chi R; Naval LC; Balane GI; Basilio R; Golubkov A; Joson ES; Lew WJ; Lofranco V; Mantala M; Pancho S; Sarol JN
    Emerg Infect Dis; 2016 Mar; 22(3):491-502. PubMed ID: 26889786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
    PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
    Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
    BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
    Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
    BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening outcomes from patients with suspected multidrug-resistant tuberculosis: lessons learned in the Philippines.
    Gler MT; Guilatco RS; Guray CV; Tupasi TE
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1326-30. PubMed ID: 22863522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Where there is hope: a qualitative study examining patients' adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
    Horter S; Stringer B; Greig J; Amangeldiev A; Tillashaikhov MN; Parpieva N; Tigay Z; du Cros P
    BMC Infect Dis; 2016 Jul; 16():362. PubMed ID: 27465783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan.
    van den Hof S; Collins D; Hafidz F; Beyene D; Tursynbayeva A; Tiemersma E
    BMC Infect Dis; 2016 Sep; 16(1):470. PubMed ID: 27595779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse treatment outcomes in multidrug resistant tuberculosis go beyond the microbe-drug interaction: Results of a multiple correspondence analysis.
    Tobón Á; Rueda J; Cáceres DH; Mejía GI; Zapata EM; Montes F; Ospina A; Fadul S; Paniagua L; Robledo J
    Biomedica; 2020 Dec; 40(4):616-625. PubMed ID: 33275341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Home is where the patient is": a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis.
    Horter S; Stringer B; Reynolds L; Shoaib M; Kasozi S; Casas EC; Verputten M; du Cros P
    BMC Health Serv Res; 2014 Feb; 14():81. PubMed ID: 24559177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Social support a key factor for adherence to multidrug-resistant tuberculosis treatment.
    Deshmukh RD; Dhande DJ; Sachdeva KS; Sreenivas AN; Kumar AMV; Parmar M
    Indian J Tuberc; 2018 Jan; 65(1):41-47. PubMed ID: 29332647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis.
    Gler MT; Podewils LJ; Munez N; Galipot M; Quelapio MI; Tupasi TE
    Int J Tuberc Lung Dis; 2012 Jul; 16(7):955-60. PubMed ID: 22584124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss-To-Follow-Up on Multidrug Resistant Tuberculosis Treatment in Gujarat, India: The WHEN and WHO of It.
    Shringarpure KS; Isaakidis P; Sagili KD; Baxi RK
    PLoS One; 2015; 10(7):e0132543. PubMed ID: 26167891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State.
    Mulu W; Mekonnen D; Yimer M; Admassu A; Abera B
    Afr Health Sci; 2015 Jun; 15(2):368-77. PubMed ID: 26124781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of adverse events in patient receiving community-based therapy for multidrug-resistant tuberculosis in Pakistan.
    Javaid A; Khan MA; Jan F; Rauf M; Khan MA; Basit A; Mehreen S
    Tuberk Toraks; 2018 Mar; 66(1):16-25. PubMed ID: 30020037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acceptability of the Medication Event Reminder Monitor for Promoting Adherence to Multidrug-Resistant Tuberculosis Therapy in Two Indian Cities: Qualitative Study of Patients and Health Care Providers.
    Thomas BE; Kumar JV; Periyasamy M; Khandewale AS; Hephzibah Mercy J; Raj EM; Kokila S; Walgude AS; Gaurkhede GR; Kumbhar JD; Ovung S; Paul M; Rajkumar BS; Subbaraman R
    J Med Internet Res; 2021 Jun; 23(6):e23294. PubMed ID: 34110300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmatic challenges in managing multidrug-resistant tuberculosis in Malawi.
    Charlie L; Saidi B; Getachew E; Wanjiru CL; Abebe M; Tesfahunei HA; Atim MG; Manyazewal T; Mlera RN
    Int J Mycobacteriol; 2021; 10(3):255-259. PubMed ID: 34494563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to the MDR-TB intensive phase treatment protocol amongst individuals followed up at central and peripheral health care facilities in Uganda - a descriptive study.
    Mukasa J; Kayongo E; Kawooya I; Lukoye D; Etwom A; Mugabe F; Tweya H; Izizinga R; Mijumbi-Deve R
    Afr Health Sci; 2020 Jun; 20(2):625-632. PubMed ID: 33163023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.